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Abstract
Background: Mantle cell lymphoma (MCL) is an aggressive disease with short median survival. Molecularly, MCL is
defined by the t(11;14) translocation leading to overexpression of the CCND1 gene. However, recent data show that
the neural transcription factor SOX11 is a disease defining antigen and several involved signaling pathways have
been pin-pointed, among others the Wnt/β-catenin pathway that is of importance for proliferation in MCL.
Therefore, we evaluated a compound library focused on the Wnt pathway with the aim of identifying Wnt-related
targets that regulate growth and survival in MCL, with particular focus on SOX11-dependent growth regulation.
Methods: An inducible SOX11 knock-down system was used to functionally screen a library of compounds (n = 75)
targeting the Wnt signaling pathway. A functionally interesting target, vacuolar-type H+-ATPase (V-ATPase), was
further evaluated by western blot, siRNA-mediated gene silencing, immunofluorescence, and flow cytometry.
Results: We show that 15 out of 75 compounds targeting the Wnt pathway reduce proliferation in all three MCL
cell lines tested. Furthermore, three substances targeting two different targets (V-ATPase and Dkk1) showed SOX11-
dependent activity. Further validation analyses were focused on V-ATPase and showed that two independent
V-ATPase inhibitors (bafilomycin A1 and concanamycin A) are sensitive to SOX11 levels, causing reduced anti-
proliferative response in SOX11 low cells. We further show, using fluorescence imaging and flow cytometry,
that V-ATPase is mainly localized to the plasma membrane in primary and MCL cell lines.
Conclusions: We show that SOX11 status affect V-ATPase dependent pathways, and thus may be involved in
regulating pH in intracellular and extracellular compartments. The plasma membrane localization of V-ATPase
indicates that pH regulation of the immediate extracellular compartment may be of importance for receptor
functionality and potentially invasiveness in vivo.
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Background
Mantle cell lymphoma (MCL) is an aggressive subtype
of B cell lymphoma, with only 5 year median survival
[1]. The disease is defined by the t(11;14) translocation,
resulting in overexpression of the CCND1 gene and
subsequent promotion of G1 to S cell cycle transition.
Additional specific disease marker include the neural
transcription factor, SOX11, overexpressed in >95 % of
MCL cases [2, 3]. Despite recent major therapeutic
progress, relapses are common and long-term survival
remains poor, and novel targets with curative potential
are sought among pathways important for MCL cell
survival.
Functionally, MCL is characterized by a number of dif-
ferent genetic aberrations [4], and efforts have focused
on targeting the constitutive NFĸB signaling [5], BTK [6]
but also Wnt signaling. Wnt signaling is of vital im-
portance both for promotion of lymphomagenesis in
* Correspondence: sara.ek@immun.lth.se
1Department of Immunotechnology, Lund University, Medicon Village,
Scheelevägen 8, 223 87 Lund, Sweden
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Emruli et al. BMC Cancer  (2016) 16:493 
DOI 10.1186/s12885-016-2550-4
MCL [7], but also for survival and evolution, as
assessed by gene expression analysis [8, 9]. In a previ-
ous siRNA screen, we identified the Wnt receptor
FZD2 to be functionally active and affecting prolifera-
tion in MCL [10]. Wnt is of importance in a wide
variety of tumors and may be specifically interesting
for development of therapies that target cancer stem
cells [11], with limited off-target effects [12]. This po-
tential has recently been demonstrated in MCL where
Wnt-targeting substances were particularly effective in
eradication of lymphoma-initiating cells [13].
We and others have shown that the neural transcrip-
tional factor SOX11 is a highly specific diagnostic [2],
functional [14–16], and prognostic antigen [17]. SOX11
has been shown to act through a number of signaling
pathways, including TGF-β signaling [14], plasmacytic
differentiation [18], angiogenesis [19], but also Wnt [20].
Homologous transcription factors to SOX11, the SOX C
family, have also been shown to interact with Wnt [21].
With the aim to identify novel targets for therapy in
MCL through search at the intersection of SOX11/Wnt
signaling, we performed a compound evaluation of an
annotated library with 75 compounds interacting either
as inhibitors or activators of the Wnt-signaling pathway,
and investigated (i) the stand-alone effect and (ii) the
SOX11-dependent effect on proliferation in MCL cells.
Results showed that among the evaluated 75 sub-
stances affecting Wnt-signaling, 15 compounds resulted
in reduced proliferation in all the three different MCL
cell lines evaluated. Further, upon filtering for differen-
tial response in relation to SOX11 level, three substances
directed to two different targets (V-ATPase and Dkk1)
were identified. Further validation studies were focused
on substances targeting V-ATPase, and confirmed that
both the V-ATPase specific inhibitors bafilomycin A1
and the analogue concanamycin A result in SOX11-
dependent growth reduction. V-ATPase is a known
regulator of intra- and extracellular pH, thus normal ex-
pression of this proton pump is of critical point for
maintenance of ideal cellular pH [22].
In this study, we show for the first time that V-ATPase
inhibitors effectively reduce proliferation in MCL cells,
are sensitive to SOX11 status and that V-ATPase is
expressed on the surface of both primary MCL cells and
cell lines, and thus an interesting therapeutic target.
Methods
Cultivation of cell lines
Three MCL cell lines, Z138, GRANTA-519 and JEKO-1,
transfected with an inducible shRNA-vector were used to
knock-down SOX11 through addition of 1 μg/ml doxycyc-
line (Sigma-Aldrich, Saint Louis, MO, USA). Briefly, cell
lines were maintained as previously described [23] in
tet-free R10 medium (RPMI-1640 (Life Technologies,
Grand Island, NY, USA) supplemented with 10 % tet-
approved fetal bovine serum (Life Technologies) and
20 μM L-glutamine (Life Technologies)), and cultured
under standard conditions (humidified atmosphere,
5 % CO2, 37 °C). SOX11 protein expression was moni-
tored over time by flow cytometry analysis, performed as
previously described [24]. Doxycycline was used to induce
down-regulation of SOX11. Thus, SOX11 high cells are
referred to as non-induced (SOX11IND-) and SOX11 low
cells as induced (SOX11IND+). SOX11IND- cells express
similar SOX11 level compared to non-transfected, wild-
type cells. All cell cultures were kept in log phase, at a
density of 0.8–2 × 106 cells/ml.
Molecular substances and reagents
Wnt pathway small molecule library was purchased from
Enzo Life Sciences (BML-2838), dissolved in DMSO
(10 mM) and stored at −80 °C. Upon treatment of cells,
the small molecules were resuspended and diluted in
tet-free R10 medium and used immediately, or stored
at +8 °C and consumed within a week. Individual
compounds bafilomycin A1 (ALX-380-063-M001) and
concanamycin A (ALX-380-034-C025) were purchased
from Enzo Life Sciences (Farmingdale, NY, USA) as
dry powders and dissolved in DMSO.
Assessment of proliferation using thymidine incorporation
Fifty thousand cells per well were plated in 96 well
Cytostar-T plates (PerkinElmer, Waltham, MA, USA)
and cultured for 24 h prior to treatment with a library of
compounds interacting with the Wnt pathway (n = 75),
at concentrations of 0.5, 2, 5 and 10 μM. Cell prolifera-
tion was evaluated 0, 24, 48 and 72 h after addition of
small molecules, by measuring incorporation of [14C]-
thymidine (PerkinElmer) using a Wallac 1450 MicroBeta
liquid scintillation counter (PerkinElmer). The relative
proliferation is presented as relative to the non-treated
control, at the specific time-point. Each data-point is rep-
resented by a minimum of three replicates (Figs. 1 and 2).
Cell viability measurements using Cell Titer Glow
Fifty thousand cells per well were plated out in 96 well
assay plates and cultured for 24 h before treatment with
Wnt-targeting small molecule library (n = 75) for up to
48 h. On the day of measurement, cells were equilibrated
for 30 min at room temperature, treated with CellTiter-
Glo reagent (Promega, Madison, WI, USA), mixed and
allowed to equilibrate for additional 10 min, before the lu-
minescent signal was recorded using a FLOUstar Omega
(BMG Labtech, Ortenberg, Germany) instrument.
Transient knock-down of V-ATPase
To obtain co-knock of V-ATPase and SOX11, Z138
SOX11IND+/SOX11IND- cells were transfected using an
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Amaxa 4D-Nucleofector (Lonza, Basel, Switzerland).
Cells, 2.5 million were resuspended in SF solution
(Lonza) and mixed with 500 nM pool of siRNA (Sigma-
Aldrich) targeting V-ATPase. In each reaction a scrambled
sequence (SCR) was used as a control.
After transfection, 50,000 cells were plated out in 96
well Cytostar-T plates, and grown for 24 h, before
treated with different concentrations of bafilomycin A1
and concanamycin A (Enzo Life Sciences), respectively,
for up to 48 h. Cell proliferation, by incorporation of
[14C]-thymidine, was measured as described above.
Immunofluorescence
Localization of V-ATPase on primary MCL cells and cell
lines was evaluated using immunofluorescence. Briefly,
50,000 cells were centrifuged onto glass slides using a
cytospin (Shandon, Pittsburgh, USA) and fixed in 4 %
paraformaldehyde for 10 min. The cells were rinsed with
PBS (Life Technologies) and blocked with 5 % FBS, 5 %
goat serum (Life Technologies) in PBS for 30 min.
Unless otherwise indicated, all incubations were carried
out at room temperature. For the primary staining, cells
were incubated with a rabbit antibody targeting the
V0a1 domain of V-ATPase (ATP6V0A1) (sc-28801,
Santa Cruz Biotechnology, Dallas, TX, USA) overnight,
and then washed with PBS. The cells were then incu-
bated with a secondary antibody, a goat anti-rabbit
IgG-Alexa 488 (Life Technologies), for 1 h. MCL cells
derived from patient samples were stained also for
CD20 expression. Briefly, these cells were incubated
for 1 h with a primary mouse anti-CD20 antibody (Dako)
followed by an equally long incubation with a secondary
goat anti-mouse IgG-Alexa 568 (Life Technologies). Fi-
nally, cell nuclei were stained with 300 nM DAPI (Life
Technologies) and the slides were mounted with ProLong
Gold anti-fade mounting medium (Life Technologies).
Fluorescence images were visualized using a fluorescence
Nikon ECLIPSE 80i microscope (Nikon Instrument Inc.,
NY, USA) equipped with a 40x objective (Nikon Plan
Fluor 40x/0.75 DIC M/N2, Nikon Instrument Inc,
Melville, NY). Images were captured using a Nikon DS-
U2/L2 USB camera (Nikon Instrument Inc, Melville, NY)
equipped with DAPI, FITC, and Texas Red filters. The
Fig. 1 V-ATPase is sensitive to SOX11 status. Assessment of cell
proliferation in stably transfected Z138 cells treated with different
concentrations of (a) bafilomycin A1, and (b) concanamycin A,
for 24 h. Mean values (n = 3 biological replicates per group) are
normalized against corresponding non-treated control samples,
and error bars indicate SEM. The significance was determined by
Student’s t-test (*P <0.05, **P <0.005)
Fig. 2 Wild-type V-ATPase level is a pre-requisite for SOX11-dependent
bafilomycin A1-induced growth inhibition. Cell lines with altered
expression of SOX11 (high/SOX11IND-, low/SOX11IND+) were transfected
with (a) a pool of siRNAs targeting V-ATPase or (b) a control siRNA
(SCR), and treated with different concentrations of bafilomycin A1 for
up to 48 h. The data here represents the 48 h time-point. a Following
treatment with bafilomycin A1, cells with knocked V-ATPase fail to
show SOX11-dependent bafilomycin A1-induced growth inhibition.
b Cells with functional V-ATPase show SOX11-dependent, bafilomycin
A1-induced growth reduction at 50 and 500 nM. Thus, we conclude
that the SOX11-dependent, V-ATPase inhibitor-induced growth
inhibition is related to the function of V-ATPase. Mean values are
normalized against corresponding non-treated control samples,
and error bars indicate SEM. The significance was determined by
Student’s t-test (*P <0.05, **P <0.005). V-ATPaseTR refers to transient
knock-down of V-ATPase, and SCRTR refers to scrambled control used
in transient knock-down experiments
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exposure times used were 10 ms DAPI, 100 ms FITC, and
400 ms Texas Red.
Flow cytometry
Cell surface expression of V-ATPase was assessed on
six different MCL cell lines and two primary samples,
using flow cytometry. In total, two different antibodies
targeting ATP6V0A1 were used (sc-28801, Santa Cruz
Biotechnology; PA5-25033, ThermoFisher, Waltham,
MA, USA). Briefly, 105 cells of interest were washed
and stained with anti-ATP6V0A1 for 30 min at 4 °C.
After washing with PBS, the cells were stained with a
secondary antibody, goat anti-rabbit IgG-FITC (BD
Pharmingen) for additional 30 min at 4 °C. Isotype
controls were included. Stained cells were washed
prior to analysis using FACS Canto II flow cytometer
(BD Bioscience). Data analysis was performed using
the software FCS Express 4 Flow Research Edition
(De Novo Software, Los Angeles, CA USA).
Statistics
The graphs were created using GraphPad Prism v.6.05
(GraphPad Software, La Jolla, CA, USA). Student’s t-
test was utilized in all analyses, unless otherwise in-
dicated. Significance in the figures is reported as *P <0.05,
**P <0.005.
Results
Screening of small molecules targeting Wnt signaling
identify V-ATPase as sensitive to SOX11 levels
A library of 75 small molecule compounds targeting
proteins of the Wnt signaling pathway (Additional file 1:
Table S1), were functionally screened in three MCL cell
lines at different concentrations. Cell proliferation was
assessed in all three cell lines, and viability in one cell line
(Z138). Fifteen substances showed >20 % reduced prolifer-
ation (compared to DMSO controls) in the three different
cell lines at minimum of two different concentrations per
cell line (Additional file 1: Table S2). Involved targets in-
clude Dkk1, GSK-3b, TCf4/ β-catenin, CK1a, LRO5/6 and
V-ATPase. In addition, seven of these substances also
showed a reduced viability (>20 %) upon treatment of
Z138 cells (Additional file 1: Table S3). Next, filtering
(cutoff: SOX11IND+/SOX11IND- >1.5 in minimum 5 out of
10 proliferation experiments) for differential response to
SOX11 level was performed, and three substances target-
ing two different targets were identified (Table 1). V-
ATPase, a specific inhibitor of vacuolar-type H+−ATPase,
was selected for further validation and functional analysis.
Cellular SOX11 protein level affects treatment response
to V-ATPase inhibitors
All validation studies were performed using SOX11 high
and low Z138 MCL cell line. Cells were treated with
different concentrations of bafilomycin A1, and prolifer-
ation was measured 0, 24, 48 and 72 h after treatment.
Already after 24 h, SOX11 high cells (SOX11IND-) were
shown to be more sensitive than SOX11 low cells
(SOX11IND+), when treated with ≥10 nM bafilomycin A1
(Fig. 1a). The difference in treatment response was
however, only significant at 50 nM. The narrow concen-
tration range for specific bafilomycin A1 induced V-
ATPase inhibition has also been seen in previous studies
[25, 26]. Using a second V-ATPase inhibitor, concana-
mycin A, we could confirm the V-ATPase specific,
SOX11-dependent growth reduction (Fig. 1b). Also con-
canamycin A show a narrow concentration range for
SOX11-dependent growth inhibition, although at lower
concentrations (5 and 10 nM). In accordance to previous
studies on V-ATPase inhibition, concanamycin A showed
a stronger potency compared to bafilomycin A1 [27, 28].
siRNA mediated knock-down of V-ATPase abolish the
difference in bafilomycin A1 sensitivity between SOX11
high and low cells
To further validate that SOX11-dependent growth in-
hibition induced by bafilomycin A1 and concanamycin
A is related to V-ATPase activity, we investigated if
the sensitivity to bafilomycin A1 is altered upon tran-
sient knock-down of V-ATPase. Cells with modified
expression of SOX11 were transfected with siRNA
targeting V-ATPase or a SCR control. Cells with reduced
V-ATPase level showed no SOX11-dependent, bafilo-
mycin A1 induced growth inhibition (Fig. 2a). As ex-
pected, control experiment (using scrambled control)
demonstrate SOX11-dependent bafilomycin A1 in-
duced growth reduction (Fig. 2b). Thus, SOX11-
dependent sensitivity to V-ATPase inhibitors is
dependent on wild-type V-ATPase levels.
Cellular protein levels of V-ATPase and SOX11 are not
co-regulated
The difference observed between SOX11 high and low
cells in response to treatment with bafilomycin A1 and
concanamycin A, respectively, made us investigate the
relationship betweeen the target protein, V-ATPase,
and SOX11. Gene expression data (Additional file 2:
Figure S1a) vagely pointed towards an anti-correlation
Table 1 Substances with SOX11-dependent inhibition of
proliferation
Drug Target Mean SOX11IND+/SOX11IND-
bafilomycin A1 V-ATPase 6.6
trichostatin A Dkk1 25.1
5-Aza-2-deoxycytidine (decitabine) Dkk1 2.5
Mean ratios of SOX11IND+/SOX11IND- calculated from GRANTA-519, JEKO-1
and Z138
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between V-ATPase and SOX11. However, this could
not be confirmed using RT-PCR (data not shown),
western blot analysis (Additional file 2: Figure S1b) or
immunofluoresence (data not shown). Thus, the difference
in response to V-ATPase inhibitors can not be explained
by a difference in V-ATPase protein level in SOX11 high/
low cells.
Immunofluoresence and flow cytometry analysis show
that V-ATPase are found at the plasma membrane of cells
V-ATPases are known to be expressed in the membrane
of intracellular organells, but also at the plasma
membrane of certain cells [29]. Plasma membrane
localization of V-ATPase has been reported as function-
ally important for tumor invasiveness and metastasis in
a number of tumors [30, 31]. Thus, to investigate the
localization of V-ATPase in both MCL primary cells and
cell lines, we performed immunofluoresence staining by
using a commercially available antibody targeting the
membrane associated domain V0a1, ATP6V0A1 (Fig. 3).
In both cases, expression of V-ATPase was shown to be
located at, but not limited to, the plasma membrane.
To further confirm the cell surface expression of V-
ATPase and investigate if the protein is accesible for spe-
cific antibodies, flow cytometry analyses were performed
using both primary MCL samples (n = 2) and cell lines
(n = 7). Two commercially available antibodies targeting
the a1 subunit of the V0 domain were used. In general,
lower signal intesities were acquired for the sc-28801
compared to the PA525033 V0a1 specific V-ATPase tar-
geting antibody. However, similar variation in V-ATPase
levels across the different samples were detected for
both antibodies (Fig. 4). JEKO-1 and MCL patient sam-
ple 1 showed highest level of ATP6V0A1 among the an-
alyzed samples, whereas UPN2, MINO and JVM2
showed a limited surface expression of this subunit.
In summary, using a Wnt-specific molecular library, we
identified bafilomycin A1 as a potent SOX11-dependent
inhibitor of growth in MCL cells. The SOX11-dependent
effect of V-ATPase inhibitors (bafilomycin A1 and
concanamycin A) was dependent on wild-type levels
of V-ATPase, as assessed by knock-down experiments.
We further show that V-ATPase is located at the
plasma membrane in MCL cells, and thus of potential
importance for tumor metastasis and invasiveness in
these tumors.
Discussion
Wnt signaling has a profound effect on MCL [7–9] and
a recent study points to a connection with SOX11, a
disease-defining antigen in MCL [20]. With the aim of
identifying novel targets for therapeutic intervention of
MCL, we have searched for targets at the cross-section
of Wnt and SOX11 signaling.
To identify Wnt-related small molecules with anti-
proliferative effect, and specifically responsive to SOX11
levels, a compound evaluation using an annotated library
targeting the Wnt-pathway was performed. Within the
Fig. 3 V-ATPase is localized at the plasma cell membrane in primary and MCL cell lines. Localization of V-ATPase in (a) Z138 control cells (SCRTR),
transiently V-ATPase knocked Z138 cells (V-ATPaseTR), and (b) primary MCL cells. Cells were centrifuged on glass slides and stained for V-ATPase.
The nuclei were counterstained by DAPI. MCL primary cells were also stained for CD20 to visualize tumor cells. The MCL control sample was not
treated with any primary antibody. All staining’s were analyzed using a Nikon ECLIPSE 80i fluorescence microscope
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Wnt-pathway targeting library, 15 out of 75 molecular
compounds had the capacity to reduce proliferation in
three different MCL cell lines. Functional targets include
Dkk1, GSK-3b, TCF4/ β-catenin, CK1a, LRO5/6 and
V-ATPase. Further, by comparing the effect in SOX11
high and low cells, three substances with SOX11-
dependent effect on proliferation were identified (aza-2
deoxycytidine/Dkk1, trichostatin A/Dkk1 and bafilomycin
A1/V-ATPase). Further validation and characterization
was focused on V-ATPase as a potential target using both
bafilomycin A1 and an analogue, concanamycin A, as spe-
cific V-ATPase targeting substances. The potential of bafi-
lomycin A1 to target V-ATPase and suppress proliferation
was described by Tashiro and colleagues in 1993 [32] and
later, further characterization of the families of bafilomy-
cins and concanamycins as specific V-ATPase inhibitors
was performed [33].
Experiments show that both bafilomycin A1 and
concanamycin A exert anti-proliferative effect and
induce cell death in MCL cell lines. A significant
difference in response between SOX11 high and low
expressing cell lines is seen at concentrations (ca
10–50 nM) where bafilomycin A1 and concanamycin
A are reported to be specific for V-ATPase, with no
off-target effect [25, 26]. Using siRNA-mediated
knock-down of V-ATPase, the SOX11-dependent sensi-
tivity to bafilomycin A1 inhibition was also shown to
be dependent on normal V-ATPase levels, thus we
conclude that the effect is specifically related to V-
ATPase function.
V-ATPase is an ATP-driven enzyme that transforms
the energy of ATP hydrolysis to electrochemical poten-
tial difference of protons across diverse biological mem-
branes via the primary active transport of H+ [22]. Thus,
V-ATPase has a major function as regulator of intra-
and extracellular pH, and normal expression of this pro-
ton pump is of critical point for maintenance of ideal
cellular pH. Overexpression of V-ATPase has been re-
ported in several tumors where it has shown to promote
acidification of the extracellular environment, and thus
favor tumor growth [34, 35] invasiveness [36, 37] and
resistance to cytotoxic agents [38, 39]. The function
of V-ATPase has recently been reviewed more extensively
elsewhere [29]. It has further been shown that Wnt
signaling is dependent on acidification and thus, func-
tional V-ATPase that can mediate proton fluxes con-
tribute to normal Fz receptor function and successful
Wnt signaling [40, 41].
In order to exclude that V-ATPase levels are different
in SOX11 high and low cells, the level of V-ATPase
was studied using gene expression analysis, western
blot (WB) and immunofluorescence. Upon gene ex-
pression mining, correlation analysis indicated that
SOX11 and V-ATPase might be anti-regulated, but
this could not be confirmed with either RT-PCR or
western blot analysis. Visual examination of fluores-
cence imaging of individual cells, could not either de-
tect any difference. Thus, we conclude that difference
in V-ATPase inhibition upon SOX11 regulation is not
related to a differential level of V-ATPase protein in
SOX11 high versus low cells.
It has been reported that a number of different tumor
cells express V-ATPase at the plasma membrane [30].
The activity of V-ATPase at the plasma membrane has
been linked to metastatic potential, suggesting that V-
ATPase provides acidic extracellular environment neces-
sary for invasion. We used antibodies targeting the V0a1
domain to investigate if the V-ATPase complex was
present in the plasma membrane. Fluoresence micros-
copy image analysis showed that V-ATPase is clearly
present in the plasma membrane, but likely also to a
lesser extent in other intracellular membranes. Flow
cytometry analysis was used to confirm that the V0a1
domain is accessible at the surface of MCL cells, and
Fig. 4 Assessment of V-ATPase cell surface expression using flow cytometry analysis. For each cell line, a ΔMFI was calculated as the difference
between the mean fluorescence intensity (MFI) of ATP6V0A1 staining compared to unstained control, (MFIATP6V0A1 – MFIcontrol). The relative
ATP6V0A1 expression was calculated by scaling all data to the cell line with the lowest ΔMFI for #PA525030 (UPN2). Error bars indicate SEM of
three technical replicates
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thus potentially able to be targeted by antibodies with
therapeutic potential.
Functionally, V-ATPase has been pin-pointed as an in-
teresting target to reduce metastatic disease [31, 42, 43],
but it is also well known that the target is toxic when
treated with small molecular inhibitors, with systemic
effect. It has been shown that the activity of V-
ATPase localized in the plasma membrane is critical
for invasion of breast cancer cells [44] and specific
isoforms have been shown to target V-ATPase to the
plasma membranes [45, 46]. Thus, the availability of
the protein on the cell surface of tumor cells may
enable antibody-based specific therapy, and would
constitute a less toxic way to target V-ATPase at the
surface of tumor cells without disrupting function in
intracellular membrane of normal cells, as penetration
of the plasma membrane by antibodies are considered
to be minimal.
Disregarding toxicity, inhibition of V-ATPase has
shown great potential to sensitize tumor cells to various
cytotoxic agents by disrupting the pH gradient between
the cell cytoplasm and lysosomal compartment. For ex-
ample, in multidrug-resistant renal epithelial cells, both
bafilomycin A1 and concanamycin A were shown to
reverse the resistance to anthracyclines [47]. Similarly,
You and colleagues [48] showed that inhibition of V-
ATPase by siRNA recovered sensitivity to chemotherapy
in breast cancer cells. Moreover, in B cell lymphoma
cells with reduced expression of CD20, induced by
bortezomib treatment, inhibition of V-ATPase led to
restorage of CD20 levels, enabling further treatment
with rituximab [49].
V-ATPase is also well known to be involved in cancer
metastasis and tumor progression. Already in late 90′
s, Ohta and colleagues showed that V-ATPase overex-
pression is characteristic for invasive pancreatic tu-
mors and suggested that V-ATPase may play a crucial
role in tumor progression [50]. Similarly, Sennoune
and colleagues [31] showed that highly metastatic and
invasive breast tumor cells exhibit a significantly
higher plasma membrane V-ATPase activity compared
to less invasive breast tumor cells. Other studies, involving
leukemic stem cells [51], esophageal squamous [39]
and non-small-cell lung cancer [52], show a direct rela-
tionship between V-ATPase expression and enhanced
drug resistance.
Conclusions
In conclusion, we provide novel information that V-
ATPase is sensitive to SOX11 levels, indicating that
SOX11 affect cellular pH regulation. V-ATPase is local-
ized on the membrane of MCL cells, and may thus be
involved in metastasis and is an interesting candidate for
antibody-based treatment.
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SOX11. However, no correlation of V-ATPase to SOX11 is visible on
b) protein level. The mRNA expression of V-ATPase was assessed by
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GAPDH expression was used as a protein-loading control for western
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